MERCK WKN: 659990 ISIN: DE0006599905 Forum: Aktien Thema: Hauptdiskussion

Vor dem Ersten Weltkrieg war das ein Unternehmen; der amerikanische Teil wurde enteignet. Seitdem darf Merck in den USA nicht mehr unter dem Markennamen „Merck“ vermarktet werden und heißt dort deshalb MilliporeSigma.

Hooper, der RSV-Impfstoff kommt von Merck Co. … 🤪

China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib 06:10 10/06/2025 June 10 (Reuters) - Merck KGaA ::CHINA'S CENTER FOR DRUG EVALUATION ACCEPTS MERCK KGAA, DARMSTADT, GERMANY'S APPLICATION FOR MARKETING AUTHORIZATION OF PIMICOTINIB.CHINA'S CENTER FOR DRUG EVALUATION ACCEPTS MERCK KGAA, DARMSTADT, GERMANY'S APPLICATION FOR MARKETING AUTHORIZATION OF PIMICOTINIB FOR TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR.

Merck: FDA approves Enflonsia RSV vaccine 10:41 10/06/2025 (CercleFinance.com) - Yesterday evening Merck announced that the US FDA has authorized Enflonsia, its vaccine to prevent respiratory syncytial virus (RSV) infections in infants. This approval will put Enflonsia in direct competition with Beyfortus, Sanofi's equivalent product, whose sales in the United States are expected to decline by 10% this year, analysts predict. Analysts expect Beyfortus' market share to come under further pressure with the arrival of this new alternative. However, the green light for Enflonsia comes amid regulatory uncertainty, with US Health Secretary Robert F. Kennedy Jr. recently dismissing all 17 members of the Advisory Committee on Immunization Practices (ACIP). Kennedy has promised to reconstitute the panel, and the next ACIP meeting, scheduled for 25-27 June, is expected to go ahead as planned, but some observers fear a possible delay that could affect the vaccine distribution schedule.

J.P. Morgan Reaffirms Their Buy Rating on Merck KGaA (0O14) TipRanks Auto-Generated Intelligence Newsdesk Jun 03, 2025, 12:07 PM J.P. Morgan Reaffirms Their Buy Rating on Merck KGaA (0O14) In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €155.00. The company’s shares closed yesterday at €114.75.